Pfizer's CEO just bought $1 million of shares while the stock trades below its 200-week moving average, an insider purchase worth noting. The dividend yields 6.4%. x.com 

Pfizer looks to be forming a multi-year low and should be a major beneficiary of AI. It pays a 6.3% dividend at a forward P/E of 8, though one more low may come in the fall. x.com 

Pfizer is a true safe haven that looks cheap at $28 a share, trading below 10 times adjusted earnings. Its 6.1% dividend has been paid for more than 349 quarters in a row, a remarkable record, and sentiment across biotech is strong after news from Moderna and Merck. x.com 

Pfizer is the kind of stock that should heavily outperform when the AI bubble pops. A dip on news that its CFO is returning to the consumer sector leaves it below 9x earnings with a 6.7% dividend yield, a payout of only around 60% of earnings. x.com 

Pfizer is cheap against its cash earnings at about 8 times, while drugmakers usually get 14 times. Fourteen times next year's cash earnings, give or take 12%, puts fair value at about $48.49-$61.71, so the $27.02 price sits 44% under the low end. This is a levels-only screen off reported earnings and revenue estimates, with no fundamental work. x.com 

Quality dividend stocks look like a great place to be over the next few years as the crowded tech trade unwinds. Per @PeterBerezinBCA, in the early dotcom bust tech crashed while the rest of the market rose, so the hedge for stocks was other stocks. A quality dividend basket holds old-economy, cash-generative businesses at sane multiples, while the index hides 50% of its weight in names at 10 times sales. That outweighs a general dislike of dividends as inefficient, taxable compounding. x.com  … Show more